{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:35:23Z","timestamp":1778254523685,"version":"3.51.4"},"reference-count":252,"publisher":"Bentham Science Publishers Ltd.","issue":"41","funder":[{"DOI":"10.13039\/501100011929","name":"COMPETE Program","doi-asserted-by":"publisher","award":["SAICTPAC\/0019\/2015"],"award-info":[{"award-number":["SAICTPAC\/0019\/2015"]}],"id":[{"id":"10.13039\/501100011929","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["UID\/QUI\/00100\/2013"],"award-info":[{"award-number":["UID\/QUI\/00100\/2013"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["UID\/DTP\/04138\/2013"],"award-info":[{"award-number":["UID\/DTP\/04138\/2013"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["PD\/BD\/135284\/2017"],"award-info":[{"award-number":["PD\/BD\/135284\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["SAICTPAC\/0019\/2015"],"award-info":[{"award-number":["SAICTPAC\/0019\/2015"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2020,1,8]]},"abstract":"<jats:sec><jats:title>:<\/jats:title><jats:p>Glycolysis is a tightly regulated process in which several enzymes, such as Hexokinases (HKs), play crucial roles. Cancer cells are characterized by specific expression levels of several isoenzymes in different metabolic pathways and these features offer possibilities for therapeutic interventions. Overexpression of HKs (mostly of the HK2 isoform) have been consistently reported in numerous types of cancer. Moreover, deletion of HK2 has been shown to decrease cancer cell proliferation without explicit side effects in animal models, which suggests that targeting HK2 is a viable strategy for cancer therapy. HK2 inhibition causes a substantial decrease of glycolysis that affects multiple pathways of central metabolism and also destabilizes the mitochondrial outer membrane, ultimately enhancing cell death. Although glycolysis inhibition has met limited success, partly due to low selectivity for specific isoforms and excessive side effects of the reported HK inhibitors, there is ample ground for progress.<\/jats:p><\/jats:sec><jats:sec><jats:title>:<\/jats:title><jats:p>The current review is focused on HK2 inhibition, envisaging the development of potent and selective anticancer agents. The information on function, expression, and activity of HKs is presented, along with their structures, known inhibitors, and reported effects of HK2 ablation\/inhibition. The structural features of the different isozymes are discussed, aiming to stimulate a more rational approach to the design of selective HK2 inhibitors with appropriate drug-like properties. Particular attention is dedicated to a structural and sequence comparison of the structurally similar HK1 and HK2 isoforms, aiming to unveil differences that could be explored therapeutically. Finally, several additional catalytic- and non-catalytic roles on different pathways and diseases, recently attributed to HK2, are reviewed and their implications briefly discussed.<\/jats:p><\/jats:sec>","DOI":"10.2174\/0929867326666181213092652","type":"journal-article","created":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T11:35:04Z","timestamp":1544700904000},"page":"7285-7322","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":182,"title":["Unlocking the Potential of HK2 in Cancer Metabolism and Therapeutics"],"prefix":"10.2174","volume":"26","author":[{"given":"Sara N.","family":"Garcia","sequence":"first","affiliation":[{"name":"Centro de Qu\u00edmica Estrutural, Instituto Superior T\u00e9cnico, Universidade de Lisboa, 1049-001 Lisboa, Portugal"}]},{"given":"Rita C.","family":"Guedes","sequence":"additional","affiliation":[{"name":"iMed.ULisboa, Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisboa, Portugal"}]},{"given":"M. Matilde","family":"Marques","sequence":"additional","affiliation":[{"name":"Centro de Qu\u00edmica Estrutural, Instituto Superior T\u00e9cnico, Universidade de Lisboa, 1049-001 Lisboa, Portugal"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"422","DOI":"10.2174\/092986708783503212","volume":"15","author":"Petrelli A.","year":"2008","unstructured":"Petrelli A.; Giordano S.; From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem 2008,15(5),422-432","journal-title":"Curr Med Chem"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.ejmech.2017.10.021","volume":"143","author":"Raghavendra N.M.","year":"2018","unstructured":"Raghavendra N.M.; Pingili D.; Kadasi S.; Mettu A.; Prasad S.V.U.M.; Dual or multi-targeting inhibitors: The next generation anticancer agents. Eur J Med Chem 2018,143(1),1277-1300","journal-title":"Eur J Med Chem"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.ejmech.2017.11.049","volume":"143","author":"Ma X.","year":"2018","unstructured":"Ma X.; Lv X.; Zhang J.; Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): An update of recent medicinal chemistry efforts. Eur J Med Chem 2018,143,449-463","journal-title":"Eur J Med Chem"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"14133","DOI":"10.18632\/oncotarget.13044","volume":"8","author":"Zhong J-T.","year":"2017","unstructured":"Zhong J-T.; Zhou S-H.; Warburg effect, hexokinase-II, and radioresistance of laryngeal carcinoma. Oncotarget 2017,8(8),14133-14146","journal-title":"Oncotarget"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.biocel.2017.12.010","volume":"95","author":"Zhang X.Y.","year":"2018","unstructured":"Zhang X.Y.; Zhang M.; Cong Q.; Zhang M.X.; Zhang M.Y.; Lu Y.Y.; Xu C.J.; Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy. Int J Biochem Cell Biol 2018,95,9-16","journal-title":"Int J Biochem Cell Biol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nrc.2016.77","volume":"16","author":"Hay N.","year":"2016","unstructured":"Hay N.; Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy? Nat Rev Cancer 2016,16(10),635-649","journal-title":"Nat Rev Cancer"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrclinonc.2016.60","volume":"14","author":"Martinez-Outschoorn U.E.","year":"2017","unstructured":"Martinez-Outschoorn U.E.; Peiris-Pag\u00e9s M.; Pestell R.G.; Sotgia F.; Lisanti M.P.; Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol 2017,14(1),11-31","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ygyno.2015.06.036","volume":"138","author":"Han J.","year":"2015","unstructured":"Han J.; Zhang L.; Guo H.; Wysham W.Z.; Roque D.R.; Willson A.K.; Sheng X.; Zhou C.; Bae-Jump V.L.; Glucose promotes cell proliferation, glucose uptake and invasion in endometrial cancer cells via AMPK\/mTOR\/S6 and MAPK signaling. Gynecol Oncol 2015,138(3),668-675","journal-title":"Gynecol Oncol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"63551","DOI":"10.18632\/oncotarget.18854","volume":"8","author":"Sun L.","year":"2017","unstructured":"Sun L.; Yin Y.; Clark L.H.; Sun W.; Sullivan S.A.; Tran A-Q.; Han J.; Zhang L.; Guo H.; Madugu E.; Pan T.; Jackson A.L.; Kilgore J.; Jones H.M.; Gilliam T.P.; Zhou C.; Bae-Jump V.L.; Dual inhibition of glycolysis and glutaminolysis as a therapeutic strategy in the treatment of ovarian cancer. Oncotarget 2017,8(38),63551-63561","journal-title":"Oncotarget"},{"key":"ref=10","author":"Nelson D.L.","year":"2005","unstructured":"Nelson D.L.; Cox M.M.; Lehninger, Principles of Biochemistry 2005","journal-title":"Lehninger, Principles of Biochemistry"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nbt.2530","volume":"31","author":"Hu J.","year":"2013","unstructured":"Hu J.; Locasale J.W.; Bielas J.H.; O\u2019Sullivan J.; Sheahan K.; Cantley L.C.; Vander Heiden M.G.; Vitkup D.; Heterogeneity of tumor-induced gene expression changes in the human metabolic network. Nat Biotechnol 2013,31(6),522-529","journal-title":"Nat Biotechnol"},{"key":"ref=12","first-page":"126, pp. 65-198","author":"Wilson J.E.","year":"1995","unstructured":"Wilson J.E.; Reviews of physiology, biochemistry and pharmacology; 1995,126, pp. 65-198","journal-title":"Reviews of physiology, biochemistry and pharmacology;"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.cbd.2007.11.002","volume":"3","author":"Irwin D.M.","year":"2008","unstructured":"Irwin D.M.; Tan H.; Molecular evolution of the vertebrate hexokinase gene family: Identification of a conserved fifth vertebrate hexokinase gene. Comp Biochem Physiol Part D Genomics Proteomics 2008,3(1),96-107","journal-title":"Comp Biochem Physiol Part D Genomics Proteomics"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ccr.2013.06.014","volume":"24","author":"Patra K.C.","year":"2013","unstructured":"Patra K.C.; Wang Q.; Bhaskar P.T.; Miller L.; Wang Z.; Wheaton W.; Chandel N.; Laakso M.; Muller W.J.; Allen E.L.; Jha A.K.; Smolen G.A.; Clasquin M.F.; Robey B.; Hay N.; Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 2013,24(2),213-228","journal-title":"Cancer Cell"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41467-017-02733-4","volume":"9","author":"DeWaal D.","year":"2018","unstructured":"DeWaal D.; Nogueira V.; Terry A.R.; Patra K.C.; Jeon S-M.; Guzman G.; Au J.; Long C.P.; Antoniewicz M.R.; Hay N.; Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin. Nat Commun 2018,9(1),446","journal-title":"Nat Commun"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3389\/fphys.2017.00460","volume":"8","author":"Camara A.K.S.","year":"2017","unstructured":"Camara A.K.S.; Zhou Y.; Wen P.C.; Tajkhorshid E.; Kwok W.M.; Mitochondrial VDAC1: A Key gatekeeper as potential therapeutic target. Front Physiol 2017,8,460","journal-title":"Front Physiol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","volume":"168","author":"Vander Heiden M.G.","year":"2017","unstructured":"Vander Heiden M.G.; DeBerardinis R.J.; Understanding the intersections between metabolism and cancer biology. Cell 2017,168(4),657-669","journal-title":"Cell"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"581","DOI":"10.2217\/fon.09.44","volume":"5","author":"Dwarakanath B.","year":"2009","unstructured":"Dwarakanath B.; Jain V.; Targeting glucose metabolism with 2-deoxy-D-glucose for improving cancer therapy. Future Oncol 2009,5(5),581-585","journal-title":"Future Oncol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00280-012-2045-1","volume":"71","author":"Raez L.E.","year":"2013","unstructured":"Raez L.E.; Papadopoulos K.; Ricart A.D.; Chiorean E.G.; Dipaola R.S.; Stein M.N.; Rocha Lima C.M.; Schlesselman J.J.; Tolba K.; Langmuir V.K.; Kroll S.; Jung D.T.; Kurtoglu M.; Rosenblatt J.; Lampidis T.J.; A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2013,71(2),523-530","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=20","year":"2006","unstructured":"Press Release: Phase 2 and Phase 3 Clinical Trials of TH-070 in Benign Prostatic Hyperplasia (BPH) Do Not Meet Primary Endpoint Threshold Pharmaceuticals IncMay;122006","journal-title":"Press Release: Phase 2 and Phase 3 Clinical Trials of TH-070 in Benign Prostatic Hyperplasia (BPH) Do Not Meet Primary Endpoint"},{"key":"ref=21","unstructured":"PreScience Closes on Institutional Round of Financing Business WireAvailable at: https:\/\/www.businesswire.com\/news\/home\/20170426005840\/en\/PreScience-Closes-Institu-tional-Financing","journal-title":"PreScience Closes on Institutional Round of Financing"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.bbabio.2009.03.003","volume":"1787","author":"Chen Z.","year":"2009","unstructured":"Chen Z.; Zhang H.; Lu W.; Huang P.; Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvate. Biochim Biophys Acta 2009,1787(5),553-560","journal-title":"Biochim Biophys Acta"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1080\/14756366.2017.1404591","volume":"33","author":"Ning X.","year":"2018","unstructured":"Ning X.; Qi H.; Li R.; Jin Y.; McNutt M.A.; Yin Y.; Synthesis and antitumor activity of novel 2, 3-didithiocarbamate substituted naphthoquinones as inhibitors of pyruvate kinase M2 isoform. J Enzyme Inhib Med Chem 2018,33(1),126-129","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1021\/acsmedchemlett.5b00214","volume":"7","author":"Lin H.","year":"2015","unstructured":"Lin H.; Zeng J.; Xie R.; Schulz M.J.; Tedesco R.; Qu J.; Erhard K.F.; Mack J.F.; Raha K.; Rendina A.R.; Szewczuk L.M.; Kratz P.M.; Jurewicz A.J.; Cecconie T.; Martens S.; McDevitt P.J.; Martin J.D.; Chen S.B.; Jiang Y.; Nickels L.; Schwartz B.J.; Smallwood A.; Zhao B.; Campobasso N.; Qian Y.; Briand J.; Rominger C.M.; Oleykowski C.; Hardwicke M.A.; Luengo J.I.; Discovery of a novel 2,6-disubstituted glucosamine series of potent and selective hexokinase 2 inhibitors. ACS Med Chem Lett 2015,7(3),217-222","journal-title":"ACS Med Chem Lett"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.bbabio.2017.02.005","volume":"1858","author":"Amoedo N.D.","year":"2017","unstructured":"Amoedo N.D.; Obre E.; Rossignol R.; Drug discovery strategies in the field of tumor energy metabolism: Limitations by metabolic flexibility and metabolic resistance to chemotherapy. Biochim Biophys Acta Bioenerg 2017,1858(8),674-685","journal-title":"Biochim Biophys Acta Bioenerg"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.5487\/TR.2016.32.3.177","volume":"32","author":"Tran Q.","year":"2016","unstructured":"Tran Q.; Lee H.; Park J.; Kim S.H.; Park J.; Targeting cancer metabolism - revisiting the Warburg effects. Toxicol Res 2016,32(3),177-193","journal-title":"Toxicol Res"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.tcb.2017.11.006","volume":"28","author":"Wolpaw A.J.","year":"2018","unstructured":"Wolpaw A.J.; Dang C.V.; Exploiting metabolic vulnerabilities of cancer with precision and accuracy. Trends Cell Biol 2018,28(3),201-212","journal-title":"Trends Cell Biol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.ccr.2008.05.005","volume":"13","author":"Kroemer G.","year":"2008","unstructured":"Kroemer G.; Pouyssegur J.; Tumor cell metabolism: cancer\u2019s Achilles\u2019 heel. Cancer Cell 2008,13(6),472-482","journal-title":"Cancer Cell"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1126\/science.123.3191.309","volume":"123","author":"Warburg O.","year":"1956","unstructured":"Warburg O.; On the origin of cancer cells. Science 1956,123(3191),309-314","journal-title":"Science"},{"key":"ref=30","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20170508","volume":"91","author":"Zaidi H.","year":"2018","unstructured":"Zaidi H.; Karakatsanis N.; Towards enhanced PET quantification in clinical oncology. Br J Radiol 2018,91(1081)","journal-title":"Br J Radiol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","volume":"41","author":"Liberti M.V.","year":"2016","unstructured":"Liberti M.V.; Locasale J.W.; The warburg effect: how does it benefit cancer cells? Trends Biochem Sci 2016,41(3),211-218","journal-title":"Trends Biochem Sci"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.addr.2009.05.010","volume":"61","author":"Pathania D.","year":"2009","unstructured":"Pathania D.; Millard M.; Neamati N.; Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Adv Drug Deliv Rev 2009,61(14),1250-1275","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13578-017-0190-2","volume":"7","author":"Singh D.","year":"2017","unstructured":"Singh D.; Arora R.; Kaur P.; Singh B.; Mannan R.; Arora S.; Overexpression of hypoxia-inducible factor and metabolic pathways: possible targets of cancer. Cell Biosci 2017,7,62","journal-title":"Cell Biosci"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.3892\/or.2015.4077","volume":"34","author":"Cervantes-Madrid D.","year":"2015","unstructured":"Cervantes-Madrid D.; Due\u00f1as-Gonz\u00e1lez A.; Antitumor effects of a drug combination targeting glycolysis, glutaminolysis and de novo synthesis of fatty acids. Oncol Rep 2015,34(3),1533-1542","journal-title":"Oncol Rep"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"7610","DOI":"10.1074\/jbc.M109950200","volume":"277","author":"Pastorino J.G.","year":"2002","unstructured":"Pastorino J.G.; Shulga N.; Hoek J.B.; Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J Biol Chem 2002,277(9),7610-7618","journal-title":"J Biol Chem"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"17422","DOI":"10.1016\/S0021-9258(19)77853-3","volume":"263","author":"Arora K.K.","year":"1988","unstructured":"Arora K.K.; Pedersen P.L.; Functional significance of mitochondrial bound hexokinase in tumor cell metabolism. Evidence for preferential phosphorylation of glucose by intramitochondrially generated ATP. J Biol Chem 1988,263(33),17422-17428","journal-title":"J Biol Chem"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.bbabio.2017.03.002","volume":"1858","author":"Mazure N.M.","year":"2017","unstructured":"Mazure N.M.; VDAC in cancer. Biochim Biophys Acta Bioenerg 2017,1858(8),665-673","journal-title":"Biochim Biophys Acta Bioenerg"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/ki.2010.532","volume":"79","author":"Gall J.M.","year":"2011","unstructured":"Gall J.M.; Wong V.; Pimental D.R.; Havasi A.; Wang Z.; Pastorino J.G.; Bonegio R.G.B.; Schwartz J.H.; Borkan S.C.; Hexokinase regulates Bax-mediated mitochondrial membrane injury following ischemic stress. Kidney Int 2011,79(11),1207-1216","journal-title":"Kidney Int"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.4161\/cc.8.20.9853","volume":"8","author":"Shulga N.","year":"2009","unstructured":"Shulga N.; Wilson-Smith R.; Pastorino J.G.; Hexokinase II detachment from the mitochondria potentiates cisplatin induced cytotoxicity through a caspase-2 dependent mechanism. Cell Cycle 2009,8(20),3355-3364","journal-title":"Cell Cycle"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.2174\/0929867033457269","volume":"10","author":"Pastorino J.G.","year":"2003","unstructured":"Pastorino J.G.; Hoek J.B.; Hexokinase II: the integration of energy metabolism and control of apoptosis. Curr Med Chem 2003,10(16),1535-1551","journal-title":"Curr Med Chem"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1517\/14728222.2013.833607","volume":"17","author":"Krasnov G.S.","year":"2013","unstructured":"Krasnov G.S.; Dmitriev A.A.; Lakunina V.A.; Kirpiy A.A.; Kudryavtseva A.V.; Targeting VDAC-bound hexokinase II: a promising approach for concomitant anti-cancer therapy. Expert Opin Ther Targets 2013,17(10),1221-1233","journal-title":"Expert Opin Ther Targets"},{"key":"ref=42","author":"Tidmarsh G.","year":"2004","unstructured":"Tidmarsh G.; Combination therapies for the treatment of cancer. WO2004064734A2 2004","journal-title":"WO2004064734A2"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.carres.2016.06.001","volume":"432","author":"Conway L.P.","year":"2016","unstructured":"Conway L.P.; Voglmeir J.; Functional analysis of anomeric sugar kinases. Carbohydr Res 2016,432,23-30","journal-title":"Carbohydr Res"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S0167-4889(97)00150-X","volume":"1401","author":"C\u00e1rdenas M.L.","year":"1998","unstructured":"C\u00e1rdenas M.L.; Cornish-Bowden A.; Ureta T.; Evolution and regulatory role of the hexokinases. Biochim Biophys Acta 1998,1401(3),242-264","journal-title":"Biochim Biophys Acta"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"D158","DOI":"10.1093\/nar\/gkw1099","volume":"45","year":"2017","unstructured":"UniProt: the universal protein knowledgebase. Nucleic Acids Res The UniProt Consortium2017,45(D1),D158-D169","journal-title":"Nucleic Acids Res"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.cbpb.2008.11.004","volume":"152","author":"Gonz\u00e1lez-Alvarez R.","year":"2009","unstructured":"Gonz\u00e1lez-Alvarez R.; Ortega-Cuellar D.; Hern\u00e1ndez-Mendoza A.; Moreno-Arriola E.; Villase\u00f1or-Mendoza K.; G\u00e1lvez-Mariscal A.; P\u00e9rez-Cruz M.E.; Morales-Salas I.; Vel\u00e1zquez-Arellano A.; The hexokinase gene family in the zebrafish: structure, expression, functional and phylogenetic analysis. Comp Biochem Physiol B Biochem Mol Biol 2009,152(2),189-195","journal-title":"Comp Biochem Physiol B Biochem Mol Biol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.gene.2013.10.068","volume":"535","author":"Li M.","year":"2014","unstructured":"Li M.; Gao Z.; Wang Y.; Wang H.; Zhang S.; Identification, expression and bioactivity of hexokinase in amphioxus: insights into evolution of vertebrate hexokinase genes. Gene 2014,535(2),318-326","journal-title":"Gene"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/0888-7543(91)90027-C","volume":"11","author":"Griffin L.D.","year":"1991","unstructured":"Griffin L.D.; Gelb B.D.; Wheeler D.A.; Davison D.; Adams V.; McCabe E.R.B.; Mammalian hexokinase 1: evolutionary conservation and structure to function analysis. Genomics 1991,11(4),1014-1024","journal-title":"Genomics"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1006\/abbi.1996.0186","volume":"329","author":"Tsai H.J.","year":"1996","unstructured":"Tsai H.J.; Wilson J.E.; Functional organization of mammalian hexokinases: both N- and C-terminal halves of the rat type II isozyme possess catalytic sites. Arch Biochem Biophys 1996,329(1),17-23","journal-title":"Arch Biochem Biophys"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"350","DOI":"10.5483\/BMBRep.2009.42.6.350","volume":"42","author":"Ahn K.J.","year":"2009","unstructured":"Ahn K.J.; Kim J.; Yun M.; Park J.H.; Lee J.D.; Enzymatic properties of the N- and C-terminal halves of human hexokinase II. BMB Rep 2009,42(6),350-355","journal-title":"BMB Rep"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/0305-0491(82)90461-8","volume":"71","author":"Ureta T.","year":"1982","unstructured":"Ureta T.; The comparative isozymology of vertebrate hexokinases. Comp Biochem Physiol B 1982,71(4),549-555","journal-title":"Comp Biochem Physiol B"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1242\/jeb.00241","volume":"206","author":"Wilson J.E.","year":"2003","unstructured":"Wilson J.E.; Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol 2003,206(Pt 12),2049-2057","journal-title":"J Exp Biol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.bbrc.2010.03.129","volume":"394","author":"Neary C.L.","year":"2010","unstructured":"Neary C.L.; Pastorino J.G.; Nucleocytoplasmic shuttling of hexokinase II in a cancer cell. Biochem Biophys Res Commun 2010,394(4),1075-1081","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1002\/jcp.24361","volume":"228","author":"Neary C.L.","year":"2013","unstructured":"Neary C.L.; Pastorino J.G.; Akt inhibition promotes hexokinase 2 redistribution and glucose uptake in cancer cells. J Cell Physiol 2013,228(9),1943-1948","journal-title":"J Cell Physiol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1038\/sj.onc.1209595","volume":"25","author":"Robey R.B.","year":"2006","unstructured":"Robey R.B.; Hay N.; Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene 2006,25(34),4683-4696","journal-title":"Oncogene"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1006\/abbi.1996.9850","volume":"338","author":"Tsai H.J.","year":"1997","unstructured":"Tsai H.J.; Wilson J.E.; Functional organization of mammalian hexokinases: characterization of the rat type III isozyme and its chimeric forms, constructed with the N- and C-terminal halves of the type I and type II isozymes. Arch Biochem Biophys 1997,338(2),183-192","journal-title":"Arch Biochem Biophys"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1210\/rp.56.1.195","volume":"56","author":"Postic C.","year":"2001","unstructured":"Postic C.; Shiota M.; Magnuson M.A.; Cell-specific roles of glucokinase in glucose homeostasis. Recent Prog Horm Res 2001,56,195-217","journal-title":"Recent Prog Horm Res"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1021\/acs.biochem.8b00022","volume":"57","author":"Sternisha S.M.","year":"2018","unstructured":"Sternisha S.M.; Liu P.; Marshall A.G.; Miller B.G.; Mechanistic origins of enzyme activation in human glucokinase variants associated with congenital hyperinsulinism. Biochemistry 2018,57(10),1632-1639","journal-title":"Biochemistry"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.2337\/dc14-2769","volume":"38","author":"Chakera A.J.","year":"2015","unstructured":"Chakera A.J.; Steele A.M.; Gloyn A.L.; Shepherd M.H.; Shields B.; Ellard S.; Hattersley A.T.; Recognition and management of individuals with hyperglycemia because of a heterozygous glucokinase mutation. Diabetes Care 2015,38(7),1383-1392","journal-title":"Diabetes Care"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.molmet.2014.12.007","volume":"4","author":"Haeusler R.A.","year":"2014","unstructured":"Haeusler R.A.; Camastra S.; Astiarraga B.; Nannipieri M.; Anselmino M.; Ferrannini E.; Decreased expression of hepatic glucokinase in type 2 diabetes. Mol Metab 2014,4(3),222-226","journal-title":"Mol Metab"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejphar.2018.02.036","volume":"826","author":"Lei L.","year":"2018","unstructured":"Lei L.; Liu S.; Li Y.; Song H.; He L.; Liu Q.; Sun S.; Li Y.; Feng Z.; Shen Z.; The potential role of glucokinase activator SHP289-04 in anti-diabetes and hepatic protection. Eur J Pharmacol 2018,826,17-23","journal-title":"Eur J Pharmacol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrd2850","volume":"8","author":"Matschinsky F.M.","year":"2009","unstructured":"Matschinsky F.M.; Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 2009,8(5),399-416","journal-title":"Nat Rev Drug Discov"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1016\/j.bmcl.2017.04.041","volume":"27","author":"Cheruvallath Z.S.","year":"2017","unstructured":"Cheruvallath Z.S.; Gwaltney S.L.; Sabat M.; Tang M.; Wang H.; Jennings A.; Hosfield D.; Lee B.; Wu Y.; Halkowycz P.; Grimshaw C.E.; Discovery of potent and orally active 1,4-disubstituted indazoles as novel allosteric glucokinase activators. Bioorg Med Chem Lett 2017,27(12),2678-2682","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1055\/s-2001-15418","volume":"33","author":"Toyoda Y.","year":"2001","unstructured":"Toyoda Y.; Tsuchida A.; Iwami E.; Shironoguchi H.; Miwa I.; Regulation of hepatic glucose metabolism by translocation of glucokinase between the nucleus and the cytoplasm in hepatocytes. Horm Metab Res 2001,33(6),329-336","journal-title":"Horm Metab Res"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.bbrep.2017.09.004","volume":"12","author":"Ali A.","year":"2017","unstructured":"Ali A.; Wathes D.C.; Swali A.; Burns H.; Burns S.; A novel mammalian glucokinase exhibiting exclusive inorganic polyphosphate dependence in the cell nucleus. Biochem Biophys Rep 2017,12,151-157","journal-title":"Biochem Biophys Rep"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.bbrc.2004.01.103","volume":"315","author":"Ronimus R.S.","year":"2004","unstructured":"Ronimus R.S.; Morgan H.W.; Cloning and biochemical characterization of a novel mouse ADP-dependent glucokinase. Biochem Biophys Res Commun 2004,315(3),652-658","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"6069","DOI":"10.1038\/ncomms7069","volume":"6","author":"Guo C.","year":"2015","unstructured":"Guo C.; Ludvik A.E.; Arlotto M.E.; Hayes M.G.; Armstrong L.L.; Scholtens D.M.; Brown C.D.; Newgard C.B.; Becker T.C.; Layden B.T.; Lowe W.L.; Reddy T.E.; Coordinated regulatory variation associated with gestational hyperglycaemia regulates expression of the novel hexokinase HKDC1. Nat Commun 2015,6,6069","journal-title":"Nat Commun"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1210\/en.2016-1288","volume":"157","author":"Ludvik A.E.","year":"2016","unstructured":"Ludvik A.E.; Pusec C.M.; Priyadarshini M.; Angueira A.R.; Guo C.; Lo A.; Hershenhouse K.S.; Yang G.Y.; Ding X.; Reddy T.E.; Lowe W.L.; Layden B.T.; HKDC1 is a novel hexokinase involved in whole-body glucose use. Endocrinology 2016,157(9),3452-3461","journal-title":"Endocrinology"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.2337\/db12-1692","volume":"62","author":"Hayes M.G.","year":"2013","unstructured":"Hayes M.G.; Urbanek M.; Hivert M.F.; Armstrong L.L.; Morrison J.; Guo C.; Lowe L.P.; Scheftner D.A.; Pluzhnikov A.; Levine D.M.; McHugh C.P.; Ackerman C.M.; Bouchard L.; Brisson D.; Layden B.T.; Mirel D.; Doheny K.F.; Leya M.V.; Lown-Hecht R.N.; Dyer A.R.; Metzger B.E.; Reddy T.E.; Cox N.J.; Lowe W.L.; Jr. HAPO study cooperative research group. Identification of HKDC1 and BACE2 as genes influencing glycemic traits during pregnancy through genome-wide association studies. Diabetes 2013,62(9),3282-3291","journal-title":"Diabetes"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/ahg.12155","volume":"80","author":"Kanthimathi S.","year":"2016","unstructured":"Kanthimathi S.; Liju S.; Laasya D.; Anjana R.M.; Mohan V.; Radha V.; Hexokinase domain containing 1 (HKDC1) gene variants and their association with gestational diabetes mellitus in a south indian population. Ann Hum Genet 2016,80(4),241-245","journal-title":"Ann Hum Genet"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.bbrc.2016.05.007","volume":"474","author":"Zhang Z.","year":"2016","unstructured":"Zhang Z.; Huang S.; Wang H.; Wu J.; Chen D.; Peng B.; Zhou Q.; High expression of hexokinase domain containing 1 is associated with poor prognosis and aggressive phenotype in hepatocarcinoma. Biochem Biophys Res Commun 2016,474(4),673-679","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1093\/bioinformatics\/btt606","volume":"30","author":"Li G.H.","year":"2014","unstructured":"Li G.H.; Huang J.F.; Inferring therapeutic targets from heterogeneous data: HKDC1 is a novel potential therapeutic target for cancer. Bioinformatics 2014,30(6),748-752","journal-title":"Bioinformatics"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/0022-2836(78)90374-1","volume":"123","author":"Anderson C.M.","year":"1978","unstructured":"Anderson C.M.; Stenkamp R.E.; Steitz T.A.; Sequencing a protein by x-ray crystallography. II. Refinement of yeast hexokinase B co-ordinates and sequence at 2.1 A resolution. J Mol Biol 1978,123(1),15-33","journal-title":"J Mol Biol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"Berman H.M.","year":"2000","unstructured":"Berman H.M.; Westbrook J.; Feng Z.; Gilliland G.; Bhat T.N.; Weissig H.; Shindyalov I.N.; Bourne P.E.; The protein data bank. Nucleic Acids Res 2000,28(1),235-242","journal-title":"Nucleic Acids Res"},{"key":"ref=75","first-page":"8","author":"Nedyalkova L.","year":"2009","unstructured":"Nedyalkova L.; Tong Y.; Rabeh W.; Tempel W.; Landry R.; Arrowsmith C.H.; Edwards A.M.; Bountra C.; Weigelt J.; Bochkarev A.; Park H.; Structural Genomics Consortium (SGC) Crystal structure of the C-terminal hexokinase domain of human HK3 RSCB PDB - 3HM8 2009,8-11","journal-title":"Structural Genomics Consortium (SGC) Crystal structure of the C-terminal hexokinase domain of human HK3 RSCB PDB - 3HM8"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1074\/jbc.271.4.1849","volume":"271","author":"Ardehali H.","year":"1996","unstructured":"Ardehali H.; Yano Y.; Printz R.L.; Koch S.; Whitesell R.R.; May J.M.; Granner D.K.; Functional organization of mammalian hexokinase II. Retention of catalytic and regulatory functions in both the NH- and COOH-terminal halves. J Biol Chem 1996,271(4),1849-1852","journal-title":"J Biol Chem"},{"key":"ref=77","first-page":"5 December","author":"Rabeh W. M.","year":"2006","unstructured":"Rabeh W. M.; Zhu H.; Nedyalkova L.; Tempel W.; Wasney G.; Landry R.; Vedadi M.; Arrowsmith C. H.; Edwards A. M.; Sundstrom M.; Weigelt J.; Bochkarev A.; Park H.; Crystal structure of human hexokinase II. RSCB PDB - 2NZT; Released 2006,5 December","journal-title":"RSCB PDB - 2NZT; Released"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/811","volume":"5","author":"Mulichak A.M.","year":"1998","unstructured":"Mulichak A.M.; Wilson J.E.; Padmanabhan K.; Garavito R.M.; The structure of mammalian hexokinase-1. Nat Struct Biol 1998,5(7),555-560","journal-title":"Nat Struct Biol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/prot.21956","volume":"72","author":"Kuser P.","year":"2008","unstructured":"Kuser P.; Cupri F.; Bleicher L.; Polikarpov I.; Crystal structure of yeast hexokinase PI in complex with glucose: A classical \u201cinduced fit\u201d example revised. Proteins 2008,72(2),731-740","journal-title":"Proteins"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1107\/S1399004714026091","volume":"71","author":"Feng J.","year":"2015","unstructured":"Feng J.; Zhao S.; Chen X.; Wang W.; Dong W.; Chen J.; Shen J.R.; Liu L.; Kuang T.; Biochemical and structural study of Arabidopsis hexokinase 1. Acta Crystallogr D Biol Crystallogr 2015,71(Pt 2),367-375","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1098\/rstb.1981.0058","volume":"293","author":"Steitz T.A.","year":"1981","unstructured":"Steitz T.A.; Shoham M.; Bennett W.S.; Jr. Structural dynamics of yeast hexokinase during catalysis. Philos Trans R Soc Lond B Biol Sci 1981,293(1063),43-52","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1006\/jmbi.1998.2017","volume":"282","author":"Aleshin A.E.","year":"1998","unstructured":"Aleshin A.E.; Zeng C.; Bartunik H.D.; Fromm H.J.; Honzatko R.B.; Regulation of hexokinase I: crystal structure of recombinant human brain hexokinase complexed with glucose and phosphate. J Mol Biol 1998,282(2),345-357","journal-title":"J Mol Biol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1107\/S0907444911036729","volume":"67","author":"Petit P.","year":"2011","unstructured":"Petit P.; Antoine M.; Ferry G.; Boutin J.A.; Lagarde A.; Gluais L.; Vincentelli R.; Vuillard L.; The active conformation of human glucokinase is not altered by allosteric activators. Acta Crystallogr D Biol Crystallogr 2011,67(Pt 11),929-935","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"13598","DOI":"10.1074\/jbc.M111.274126","volume":"287","author":"Liu S.","year":"2012","unstructured":"Liu S.; Ammirati M.J.; Song X.; Knafels J.D.; Zhang J.; Greasley S.E.; Pfefferkorn J.A.; Qiu X.; Insights into mechanism of glucokinase activation: observation of multiple distinct protein conformations. J Biol Chem 2012,287(17),13598-13610","journal-title":"J Biol Chem"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0969-2126(00)80032-5","volume":"7","author":"Rosano C.","year":"1999","unstructured":"Rosano C.; Sabini E.; Rizzi M.; Deriu D.; Murshudov G.; Bianchi M.; Serafini G.; Magnani M.; Bolognesi M.; Binding of non-catalytic ATP to human hexokinase I highlights the structural components for enzyme-membrane association control. Structure 1999,7(11),1427-1437","journal-title":"Structure"},{"key":"ref=86","first-page":"170","volume":"57","author":"Smith T.A.D.","year":"2000","unstructured":"Smith T.A.D.; Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci 2000,57(2),170-178","journal-title":"Br J Biomed Sci"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"16690","DOI":"10.1074\/jbc.271.28.16690","volume":"271","author":"Osawa H.","year":"1996","unstructured":"Osawa H.; Sutherland C.; Robey R.B.; Printz R.L.; Granner D.K.; Analysis of the signaling pathway involved in the regulation of hexokinase II gene transcription by insulin. J Biol Chem 1996,271(28),16690-16694","journal-title":"J Biol Chem"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"17296","DOI":"10.1074\/jbc.271.29.17296","volume":"271","author":"Osawa H.","year":"1996","unstructured":"Osawa H.; Robey R.B.; Printz R.L.; Granner D.K.; Identification and characterization of basal and cyclic AMP response elements in the promoter of the rat hexokinase II gene. J Biol Chem 1996,271(29),17296-17303","journal-title":"J Biol Chem"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"351","DOI":"10.14670\/HH-11-799","volume":"32","author":"Katagiri M.","year":"2017","unstructured":"Katagiri M.; Karasawa H.; Takagi K.; Nakayama S.; Yabuuchi S.; Fujishima F.; Naitoh T.; Watanabe M.; Suzuki T.; Unno M.; Sasano H.; Hexokinase 2 in colorectal cancer: a potent prognostic factor associated with glycolysis, proliferation and migration. Histol Histopathol 2017,32(4),351-360","journal-title":"Histol Histopathol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"32332","DOI":"10.18632\/oncotarget.15974","volume":"8","author":"Wu J.","year":"2017","unstructured":"Wu J.; Hu L.; Wu F.; Zou L.; He T.; Poor prognosis of hexokinase 2 overexpression in solid tumors of digestive system: a meta-analysis. Oncotarget 2017,8(19),32332-32344","journal-title":"Oncotarget"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12876-016-0474-8","volume":"16","author":"Zhang Z.F.","year":"2016","unstructured":"Zhang Z.F.; Feng X.S.; Chen H.; Duan Z.J.; Wang L.X.; Yang D.; Liu P.X.; Zhang Q.P.; Jin Y.L.; Sun Z.G.; Liu H.; Prognostic significance of synergistic hexokinase-2 and beta2-adrenergic receptor expression in human hepatocelluar carcinoma after curative resection. BMC Gastroenterol 2016,16(1),57","journal-title":"BMC Gastroenterol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.bbrc.2017.01.139","volume":"484","author":"Thamrongwaranggoon U.","year":"2017","unstructured":"Thamrongwaranggoon U.; Seubwai W.; Phoomak C.; Sangkhamanon S.; Cha\u2019on U.; Boonmars T.; Wongkham S.; Targeting hexokinase II as a possible therapy for cholangiocarcinoma. Biochem Biophys Res Commun 2017,484(2),409-415","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"110","DOI":"10.24843\/IJBB.2017.v04.i02.p05","volume":"4","author":"Kharitonov S.","year":"2017","unstructured":"Kharitonov S.; Zikiriahodzhaev A.; Ermoshchenkova M.; Sukhot\u2019ko A.; Fedorova M.; Pudova E.; Alekseev B.; Kaprin A.; Kudryavtseva A.; Hexokinases in breast cancer. Int J Biosci Biotechnol 2017,4(2),110-116","journal-title":"Int J Biosci Biotechnol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12935-016-0280-y","volume":"16","author":"Wang H.","year":"2016","unstructured":"Wang H.; Wang L.; Zhang Y.; Wang J.; Deng Y.; Lin D.; Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth. Cancer Cell Int 2016,16,9","journal-title":"Cancer Cell Int"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"7381","DOI":"10.1128\/MCB.00440-07","volume":"27","author":"Kim J.W.","year":"2007","unstructured":"Kim J.W.; Gao P.; Liu Y.C.; Semenza G.L.; Dang C.V.; Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol 2007,27(21),7381-7393","journal-title":"Mol Cell Biol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jhep.2004.11.020","volume":"42","author":"Gwak G.Y.","year":"2005","unstructured":"Gwak G.Y.; Yoon J.H.; Kim K.M.; Lee H.S.; Chung J.W.; Gores G.J.; Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J Hepatol 2005,42(3),358-364","journal-title":"J Hepatol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1158\/0008-5472.CAN-17-1624","volume":"78","author":"Ha J.H.","year":"2018","unstructured":"Ha J.H.; Radhakrishnan R.; Jayaraman M.; Yan M.; Ward J.D.; Fung K.M.; Moxley K.; Sood A.K.; Isidoro C.; Mukherjee P.; Song Y.S.; Dhanasekaran D.N.; LPA induces metabolic reprogramming in ovarian cancer via a pseudohypoxic response. Cancer Res 2018,78(8),1923-1934","journal-title":"Cancer Res"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13578-017-0178-y","volume":"7","author":"Sun Z.","year":"2017","unstructured":"Sun Z.; Zhang W.; Li Q.; miR-125a suppresses viability and glycolysis and induces apoptosis by targeting Hexokinase 2 in laryngeal squamous cell carcinoma. Cell Biosci 2017,7,51","journal-title":"Cell Biosci"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/1471-2407-12-232","volume":"12","author":"Gregersen L.H.","year":"2012","unstructured":"Gregersen L.H.; Jacobsen A.; Frankel L.B.; Wen J.; Krogh A.; Lund A.H.; MicroRNA-143 down-regulates Hexokinase 2 in colon cancer cells. BMC Cancer 2012,12,232","journal-title":"BMC Cancer"},{"key":"ref=100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121046","volume":"10","author":"Lu C.L.","year":"2015","unstructured":"Lu C.L.; Qin L.; Liu H.C.; Candas D.; Fan M.; Li J.J.; Tumor cells switch to mitochondrial oxidative phosphorylation under radiation via mTOR-mediated hexokinase II inhibition--a Warburg-reversing effect. PLoS One 2015,10(3)","journal-title":"PLoS One"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.molcel.2013.12.019","volume":"53","author":"Roberts D.J.","year":"2014","unstructured":"Roberts D.J.; Tan-Sah V.P.; Ding E.Y.; Smith J.M.; Miyamoto S.; Hexokinase-II positively regulates glucose starvation-induced autophagy through TORC1 inhibition. Mol Cell 2014,53(4),521-533","journal-title":"Mol Cell"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"23798","DOI":"10.1074\/jbc.M113.482026","volume":"288","author":"Roberts D.J.","year":"2013","unstructured":"Roberts D.J.; Tan-Sah V.P.; Smith J.M.; Miyamoto S.; Akt phosphorylates HK-II at Thr-473 and increases mitochondrial HK-II association to protect cardiomyocytes. J Biol Chem 2013,288(33),23798-23806","journal-title":"J Biol Chem"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s11010-017-3001-5","volume":"432","author":"Kolar D.","year":"2017","unstructured":"Kolar D.; Gresikova M.; Waskova-Arnostova P.; Elsnicova B.; Kohutova J.; Hornikova D.; Vebr P.; Neckar J.; Blahova T.; Kasparova D.; Novotny J.; Kolar F.; Novakova O.; Zurmanova J.M.; Adaptation to chronic continuous hypoxia potentiates Akt\/HK2 anti-apoptotic pathway during brief myocardial ischemia\/reperfusion insult. Mol Cell Biochem 2017,432(1-2),99-108","journal-title":"Mol Cell Biochem"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1016\/j.cellsig.2014.04.015","volume":"26","author":"Hu J.W.","year":"2014","unstructured":"Hu J.W.; Sun P.; Zhang D.X.; Xiong W.J.; Mi J.; Hexokinase 2 regulates G1\/S checkpoint through CDK2 in cancer-associated fibroblasts. Cell Signal 2014,26(10),2210-2216","journal-title":"Cell Signal"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1593\/neo.04577","volume":"7","author":"Mamede M.","year":"2005","unstructured":"Mamede M.; Higashi T.; Kitaichi M.; Ishizu K.; Ishimori T.; Nakamoto Y.; Yanagihara K.; Li M.; Tanaka F.; Wada H.; Manabe T.; Saga T.; [F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia 2005,7(4),369-379","journal-title":"Neoplasia"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.celrep.2014.07.053","volume":"8","author":"Wang L.","year":"2014","unstructured":"Wang L.; Xiong H.; Wu F.; Zhang Y.; Wang J.; Zhao L.; Guo X.; Chang L.J.; Zhang Y.; You M.J.; Koochekpour S.; Saleem M.; Huang H.; Lu J.; Deng Y.; Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth. Cell Rep 2014,8(5),1461-1474","journal-title":"Cell Rep"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/hep.29462","volume":"67","author":"Lin Y.H.","year":"2018","unstructured":"Lin Y.H.; Wu M.H.; Huang Y.H.; Yeh C.T.; Cheng M.L.; Chi H.C.; Tsai C.Y.; Chung I.H.; Chen C.Y.; Lin K.H.; Taurine up-regulated gene 1 functions as a master regulator to coordinate glycolysis and metastasis in hepatocellular carcinoma. Hepatology 2018,67(1),188-203","journal-title":"Hepatology"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.yexcr.2017.09.028","volume":"360","author":"Singh A.","year":"2017","unstructured":"Singh A.; Sen E.; Reciprocal role of SIRT6 and Hexokinase 2 in the regulation of autophagy driven monocyte differentiation. Exp Cell Res 2017,360(2),365-374","journal-title":"Exp Cell Res"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1083\/jcb.201503044","volume":"210","author":"Xia H.G.","year":"2015","unstructured":"Xia H.G.; Najafov A.; Geng J.; Galan-Acosta L.; Han X.; Guo Y.; Shan B.; Zhang Y.; Norberg E.; Zhang T.; Pan L.; Liu J.; Coloff J.L.; Ofengeim D.; Zhu H.; Wu K.; Cai Y.; Yates J.R.; Zhu Z.; Yuan J.; Vakifahmetoglu-Norberg H.; Degradation of HK2 by chaperone-mediated autophagy promotes metabolic catastrophe and cell death. J Cell Biol 2015,210(5),705-716","journal-title":"J Cell Biol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/bjs.10646","volume":"105","author":"Xiao M.","year":"2018","unstructured":"Xiao M.; Lou C.; Xiao H.; Yang Y.; Cai X.; Li C.; Jia S.; Huang Y.; MiR-128 regulation of glucose metabolism and cell proliferation in triple-negative breast cancer. Br J Surg 2018,105(1),75-85","journal-title":"Br J Surg"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.3892\/ol.2016.4316","volume":"11","author":"Liu G.","year":"2016","unstructured":"Liu G.; Li Y.I.; Gao X.; Overexpression of microRNA-133b sensitizes non-small cell lung cancer cells to irradiation through the inhibition of glycolysis. Oncol Lett 2016,11(4),2903-2908","journal-title":"Oncol Lett"},{"key":"ref=112","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317706215","volume":"39","author":"Zhao X.","year":"2017","unstructured":"Zhao X.; Lu C.; Chu W.; Zhang B.; Zhen Q.; Wang R.; Zhang Y.; Li Z.; Lv B.; Li H.; Liu J.; MicroRNA-124 suppresses proliferation and glycolysis in non-small cell lung cancer cells by targeting AKT-GLUT1\/HKII. Tumour Biol 2017,39(5)","journal-title":"Tumour Biol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.3892\/or.2017.5430","volume":"37","author":"Tao T.","year":"2017","unstructured":"Tao T.; Chen M.; Jiang R.; Guan H.; Huang Y.; Su H.; Hu Q.; Han X.; Xiao J.; Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b\/HK2 axis. Oncol Rep 2017,37(3),1430-1436","journal-title":"Oncol Rep"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/CBM-160619","volume":"17","author":"Li L.Q.","year":"2016","unstructured":"Li L.Q.; Yang Y.; Chen H.; Zhang L.; Pan D.; Xie W.J.; MicroRNA-181b inhibits glycolysis in gastric cancer cells via targeting hexokinase 2 gene. Cancer Biomark 2016,17(1),75-81","journal-title":"Cancer Biomark"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.bbrc.2015.11.066","volume":"469","author":"Qin Y.","year":"2016","unstructured":"Qin Y.; Cheng C.; Lu H.; Wang Y.; miR-4458 suppresses glycolysis and lactate production by directly targeting hexokinase2 in colon cancer cells. Biochem Biophys Res Commun 2016,469(1),37-43","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"393-403, e4","DOI":"10.1016\/j.cmet.2017.12.007","volume":"27","author":"Jiang S.","year":"2018","unstructured":"Jiang S.; Yan W.; Wang S.E.; Baltimore D.; Let-7 Suppresses B cell activation through restricting the availability of necessary nutrients. Cell Metab 2018,27(2),393-403, e4","journal-title":"Cell Metab"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"13732","DOI":"10.1038\/ncomms13732","volume":"8","author":"Zhang J.","year":"2017","unstructured":"Zhang J.; Wang S.; Jiang B.; Huang L.; Ji Z.; Li X.; Zhou H.; Han A.; Chen A.; Wu Y.; Ma H.; Zhao W.; Zhao Q.; Xie C.; Sun X.; Zhou Y.; Huang H.; Suleman M.; Lin F.; Zhou L.; Tian F.; Jin M.; Cai Y.; Zhang N.; Li Q.; c-Src phosphorylation and activation of hexokinase promotes tumorigenesis and metastasis. Nat Commun 2017,8,13732","journal-title":"Nat Commun"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/1440-1681.12774","volume":"44","author":"Huang Y.P.","year":"2017","unstructured":"Huang Y.P.; Chang N.W.; Proteomic analysis of oral cancer reveals new potential therapeutic targets involved in the Warburg effect. Clin Exp Pharmacol Physiol 2017,44(8),880-887","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref=119","first-page":"4054","volume":"8","author":"Huang X.","year":"2015","unstructured":"Huang X.; Liu M.; Sun H.; Wang F.; Xie X.; Chen X.; Su J.; He Y.; Dai Y.; Wu H.; Shen L.; HK2 is a radiation resistant and independent negative prognostic factor for patients with locally advanced cervical squamous cell carcinoma. Int J Clin Exp Pathol 2015,8(4),4054-4063","journal-title":"Int J Clin Exp Pathol"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1111\/cas.12487","volume":"105","author":"Hamabe A.","year":"2014","unstructured":"Hamabe A.; Yamamoto H.; Konno M.; Uemura M.; Nishimura J.; Hata T.; Takemasa I.; Mizushima T.; Nishida N.; Kawamoto K.; Koseki J.; Doki Y.; Mori M.; Ishii H.; Combined evaluation of hexokinase 2 and phosphorylated pyruvate dehydrogenase-E1\u03b1 in invasive front lesions of colorectal tumors predicts cancer metabolism and patient prognosis. Cancer Sci 2014,105(9),1100-1108","journal-title":"Cancer Sci"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s13277-010-0109-6","volume":"32","author":"Qiu M.Z.","year":"2011","unstructured":"Qiu M.Z.; Han B.; Luo H.Y.; Zhou Z.W.; Wang Z.Q.; Wang F.H.; Li Y.H.; Xu R.H.; Expressions of hypoxia-inducible factor-1\u03b1 and hexokinase-II in gastric adenocarcinoma: the impact on prognosis and correlation to clinicopathologic features. Tumour Biol 2011,32(1),159-166","journal-title":"Tumour Biol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s12032-011-9841-z","volume":"29","author":"Gong L.","year":"2012","unstructured":"Gong L.; Cui Z.; Chen P.; Han H.; Peng J.; Leng X.; Reduced survival of patients with hepatocellular carcinoma expressing hexokinase II. Med Oncol 2012,29(2),909-914","journal-title":"Med Oncol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1158\/1541-7786.MCR-09-0234","volume":"7","author":"Palmieri D.","year":"2009","unstructured":"Palmieri D.; Fitzgerald D.; Shreeve S.M.; Hua E.; Bronder J.L.; Weil R.J.; Davis S.; Stark A.M.; Merino M.J.; Kurek R.; Mehdorn H.M.; Davis G.; Steinberg S.M.; Meltzer P.S.; Aldape K.; Steeg P.S.; Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol Cancer Res 2009,7(9),1438-1445","journal-title":"Mol Cancer Res"},{"key":"ref=124","doi-asserted-by":"publisher","DOI":"10.4161\/23723556.2014.974465","volume":"2","author":"Deng Y.","year":"2015","unstructured":"Deng Y.; Lu J.; Targeting hexokinase 2 in castration-resistant prostate cancer. Mol Cell Oncol 2015,2(3)","journal-title":"Mol Cell Oncol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1111\/cas.12238","volume":"104","author":"Sato-Tadano A.","year":"2013","unstructured":"Sato-Tadano A.; Suzuki T.; Amari M.; Takagi K.; Miki Y.; Tamaki K.; Watanabe M.; Ishida T.; Sasano H.; Ohuchi N.; Hexokinase II in breast carcinoma: a potent prognostic factor associated with hypoxia-inducible factor-1\u03b1 and Ki-67. Cancer Sci 2013,104(10),1380-1388","journal-title":"Cancer Sci"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3727\/096504015X14459480491740","volume":"23","author":"Xi F.","year":"2016","unstructured":"Xi F.; Ye J.; Inhibition of lung carcinoma A549 cell growth by knockdown of hexokinase 2 in situ and in vivo. Oncol Res 2016,23(1-2),53-59","journal-title":"Oncol Res"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1159\/000153655","volume":"54","author":"Peng Q.P.","year":"2008","unstructured":"Peng Q.P.; Zhou J.M.; Zhou Q.; Pan F.; Zhong D.P.; Liang H.J.; Downregulation of the hexokinase II gene sensitizes human colon cancer cells to 5-fluorouracil. Chemotherapy 2008,54(5),357-363","journal-title":"Chemotherapy"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.3892\/ijo.2017.3979","volume":"50","author":"Liu Y.","year":"2017","unstructured":"Liu Y.; Murray-Stewart T.; Casero R.A.; Jr.; Kagiampakis, I.; Jin, L.; Zhang, J.; Wang, H.; Che, Q.; Tong, H.; Ke, J.; Jiang, F.; Wang, F.; Wan, X. Targeting hexokinase 2 inhibition promotes radiosensitization in HPV16 E7-induced cervical cancer and suppresses tumor growth. Int J Oncol 2017,50(6),2011-2023","journal-title":"Int J Oncol"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3892\/or.2017.6155","volume":"39","author":"Wu J.","year":"2018","unstructured":"Wu J.; Zhang X.; Wang Y.; Sun Q.; Chen M.; Liu S.; Zou X.; Licochalcone A suppresses hexokinase 2-mediated tumor glycolysis in gastric cancer via downregulation of the Akt signaling pathway. Oncol Rep 2018,39(3),1181-1190","journal-title":"Oncol Rep"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13046-017-0514-4","volume":"36","author":"Xu D.","year":"2017","unstructured":"Xu D.; Jin J.; Yu H.; Zhao Z.; Ma D.; Zhang C.; Jiang H.; Chrysin inhibited tumor glycolysis and induced apoptosis in hepatocellular carcinoma by targeting hexokinase-2. J Exp Clin Cancer Res 2017,36(1),44","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"13703","DOI":"10.18632\/oncotarget.3800","volume":"6","author":"Dai W.","year":"2015","unstructured":"Dai W.; Wang F.; Lu J.; Xia Y.; He L.; Chen K.; Li J.; Li S.; Liu T.; Zheng Y.; Wang J.; Lu W.; Zhou Y.; Yin Q.; Abudumijiti H.; Chen R.; Zhang R.; Zhou L.; Zhou Z.; Zhu R.; Yang J.; Wang C.; Zhang H.; Zhou Y.; Xu L.; Guo C.; By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice. Oncotarget 2015,6(15),13703-13717","journal-title":"Oncotarget"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1002\/jcb.26742","volume":"119","author":"Gao X.","year":"2018","unstructured":"Gao X.; Han H.; Jolkinolide B inhibits glycolysis by downregulating hexokinase 2 expression through inactivating the Akt\/mTOR pathway in non-small cell lung cancer cells. J Cell Biochem 2018,119(6),4967-4974","journal-title":"J Cell Biochem"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"24148","DOI":"10.18632\/oncotarget.4376","volume":"6","author":"Chen G.Q.","year":"2015","unstructured":"Chen G.Q.; Tang C.F.; Shi X.K.; Lin C.Y.; Fatima S.; Pan X.H.; Yang D.J.; Zhang G.; Lu A.P.; Lin S.H.; Bian Z.X.; Halofuginone inhibits colorectal cancer growth through suppression of Akt\/mTORC1 signaling and glucose metabolism. Oncotarget 2015,6(27),24148-24162","journal-title":"Oncotarget"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1016\/j.bbagen.2013.03.009","volume":"1830","author":"Wei L.","year":"2013","unstructured":"Wei L.; Dai Q.; Zhou Y.; Zou M.; Li Z.; Lu N.; Guo Q.; Oroxylin A sensitizes non-small cell lung cancer cells to anoikis via glucose-deprivation-like mechanisms: c-Src and hexokinase II. Biochim Biophys Acta 2013,1830(6),3835-3845","journal-title":"Biochim Biophys Acta"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s10238-013-0250-9","volume":"14","author":"Suh D.H.","year":"2014","unstructured":"Suh D.H.; Kim M.A.; Kim H.; Kim M.K.; Kim H.S.; Chung H.H.; Kim Y.B.; Song Y.S.; Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer. Clin Exp Med 2014,14,345-353","journal-title":"Clin Exp Med"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.yjmcc.2014.09.020","volume":"78","author":"Calmettes G.","year":"2015","unstructured":"Calmettes G.; Ribalet B.; John S.; Korge P.; Ping P.; Weiss J.N.; Hexokinases and cardioprotection. J Mol Cell Cardiol 2015,78,107-115","journal-title":"J Mol Cell Cardiol"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1111\/bph.12363","volume":"171","author":"Nederlof R.","year":"2014","unstructured":"Nederlof R.; Eerbeek O.; Hollmann M.W.; Southworth R.; Zuurbier C.J.; Targeting hexokinase II to mitochondria to modulate energy metabolism and reduce ischaemia-reperfusion injury in heart. Br J Pharmacol 2014,171(8),2067-2079","journal-title":"Br J Pharmacol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.4161\/cbt.7.7.6199","volume":"7","author":"Peng Q.","year":"2008","unstructured":"Peng Q.; Zhou Q.; Zhou J.; Zhong D.; Pan F.; Liang H.; Stable RNA interference of hexokinase II gene inhibits human colon cancer LoVo cell growth in vitro and in vivo. Cancer Biol Ther 2008,7(7),1128-1135","journal-title":"Cancer Biol Ther"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"W597-600","DOI":"10.1093\/nar\/gkt376","volume":"41","author":"McWilliam H.","year":"2013","unstructured":"McWilliam H.; Li W.; Uludag M.; Squizzato S.; Park Y.M.; Buso N.; Cowley A.P.; Lopez R.; Analysis tool web services from the EMBL-EBI. Nucleic Acids Res 2013,41(Web Server issue),W597-600","journal-title":"Nucleic Acids Res"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1006\/abbi.1999.1326","volume":"369","author":"Tsai H.J.","year":"1999","unstructured":"Tsai H.J.; Functional organization and evolution of mammalian hexokinases: mutations that caused the loss of catalytic activity in N-terminal halves of type I and type III isozymes. Arch Biochem Biophys 1999,369(1),149-156","journal-title":"Arch Biochem Biophys"},{"key":"ref=141","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20171666","volume":"38","author":"Nawaz M.H.","year":"2018","unstructured":"Nawaz M.H.; Ferreira J.C.; Nedyalkova L.; Zhu H.; Carrasco-L\u00f3pez C.; Kirmizialtin S.; Rabeh W.M.; The catalytic inactivation of the N-half of human hexokinase 2 and structural and biochemical characterization of its mitochondrial conformation. Biosci Rep 2018,38(1)","journal-title":"Biosci Rep"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1006\/jmbi.1999.3494","volume":"296","author":"Aleshin A.E.","year":"2000","unstructured":"Aleshin A.E.; Kirby C.; Liu X.; Bourenkov G.P.; Bartunik H.D.; Fromm H.J.; Honzatko R.B.; Crystal structures of mutant monomeric hexokinase I reveal multiple ADP binding sites and conformational changes relevant to allosteric regulation. J Mol Biol 2000,296(4),1001-1015","journal-title":"J Mol Biol"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0969-2126(98)00006-9","volume":"6","author":"Aleshin A.E.","year":"1998","unstructured":"Aleshin A.E.; Zeng C.; Bourenkov G.P.; Bartunik H.D.; Fromm H.J.; Honzatko R.B.; The mechanism of regulation of hexokinase: new insights from the crystal structure of recombinant human brain hexokinase complexed with glucose and glucose-6-phosphate. Structure 1998,6(1),39-50","journal-title":"Structure"},{"key":"ref=144","first-page":"12 June","author":"Shen L.","year":"2013","unstructured":"Shen L.; Gao Y.; Honzatko R. B.; Inhibitor sites of unequal affinity linked by binding synergism in mutant forms of recombinant human hexokinase type-I. RSCB PDB - 4F9O, Released 2013,12 June","journal-title":"RSCB PDB - 4F9O, Released"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1517\/13543784.17.10.1533","volume":"17","author":"Scatena R.","year":"2008","unstructured":"Scatena R.; Bottoni P.; Pontoglio A.; Mastrototaro L.; Giardina B.; Glycolytic enzyme inhibitors in cancer treatment. Expert Opin Investig Drugs 2008,17(10),1533-1545","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=146","doi-asserted-by":"publisher","DOI":"10.3390\/molecules21121730","volume":"21","author":"Lis P.","year":"2016","unstructured":"Lis P.; Dyl\u0105g M.; Nied\u017awiecka K.; Ko Y.H.; Pedersen P.L.; Goffeau A.; U\u0142aszewski S.; The HK2 dependent \u201cwarburg effect\u201d and mitochondrial oxidative phosphorylation in cancer: Targets for effective therapy with 3-bromopyruvate. Molecules 2016,21(12)","journal-title":"Molecules"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.bbcan.2016.08.001","volume":"1866","author":"Nath K.","year":"2016","unstructured":"Nath K.; Guo L.; Nancolas B.; Nelson D.S.; Shestov A.A.; Lee S.C.; Roman J.; Zhou R.; Leeper D.B.; Halestrap A.P.; Blair I.A.; Glickson J.D.; Mechanism of antineoplastic activity of lonidamine. Biochim Biophys Acta 2016,1866(2),151-162","journal-title":"Biochim Biophys Acta"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2174\/1574892811666160415160104","volume":"11","author":"Sheng H.","year":"2016","unstructured":"Sheng H.; Tang W.; Glycolysis inhibitors for anticancer therapy: a review of recent patents. Recent Patents Anticancer Drug Discov 2016,11(3),297-308","journal-title":"Recent Patents Anticancer Drug Discov"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1038\/sj.onc.1209597","volume":"25","author":"Pelicano H.","year":"2006","unstructured":"Pelicano H.; Martin D.S.; Xu R.H.; Huang P.; Glycolysis inhibition for anticancer treatment. Oncogene 2006,25(34),4633-4646","journal-title":"Oncogene"},{"key":"ref=150","author":"Ko Y. H.","year":"2012","unstructured":"Ko Y. H.; Compositions and methods for the treatment of cancer. US8324175B2 2012","journal-title":"US8324175B2"},{"key":"ref=151","author":"Ricci J.-E.","year":"2012","unstructured":"Ricci J.-E.; Glycolytic inhibitor with cytotoxic agent for use in the treatment of a cancer. WO2012123774A1 2012","journal-title":"WO2012123774A1"},{"key":"ref=152","author":"Priebe W.","year":"2009","unstructured":"Priebe W.; Conrad C.; Madden T.; Fokt I.; Szymanski S.; Antonovic L.; Inhibitors of glycolysis useful in the treatment of brain tumors. WO2009108926 2009","journal-title":"WO2009108926"},{"key":"ref=153","author":"Mjalli A.M.M.","year":"2016","unstructured":"Mjalli A.M.M.; Gaddam B.; Gohimukkula D.R.; Polisetti D.R.; Rao M.; Guzel M.; Singh N.; HAJJO, R.; Andrews, R.C.; Xie, R.; Kalpathy, S.; SAHOO, S.P.; Davis, S.T. WO2016196890A1 2016","journal-title":"WO2016196890A1"},{"key":"ref=154","author":"Palazzo G.","year":"1975","unstructured":"Palazzo G.; Silvestrini B.; Substituted 1-benzyl-1Hindazole- 3-carboxylic acids and derivatives tereof. US3895026A 1975","journal-title":"US3895026A"},{"key":"ref=155","author":"Tidmarsh G.","year":"2006","unstructured":"Tidmarsh G.; Selick H.; Treatment of Benign Prostatic Hyperplasia Using Energolytic Agents. US20060172953A1 2006","journal-title":"US20060172953A1"},{"key":"ref=156","author":"Tidmarsh G.","year":"2006","unstructured":"Tidmarsh G.; Prevention of Cancer. WO2006010073A1 2006","journal-title":"WO2006010073A1"},{"key":"ref=157","author":"Matteucci M.","year":"2007","unstructured":"Matteucci M.; Rao P.; Duan J.-X.; Lonidamine Analogs. US20070043057A1 2007","journal-title":"US20070043057A1"},{"key":"ref=158","author":"Geschwind J.-F.","year":"2010","unstructured":"Geschwind J.-F.; Vali M.; Methods and compositions of 3- halopyruvate and related compounds for the treatment of cancer. US20100137434A1 2010","journal-title":"US20100137434A1"},{"key":"ref=159","author":"Ko Y. H.","year":"2010","unstructured":"Ko Y. H.; Composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer. US7754693B2 2010","journal-title":"US7754693B2"},{"key":"ref=160","author":"Ko Y. H.","year":"2011","unstructured":"Ko Y. H.; Compositions and methods for the treatment of cancer. US20110008418A1 2011","journal-title":"US20110008418A1"},{"key":"ref=161","author":"Dhar S.","year":"2015","unstructured":"Dhar S.; Marrache S.; Mitochondrial delivery of 3- bromopyruvate. WO2015138992A1 2015","journal-title":"WO2015138992A1"},{"key":"ref=162","author":"Ko Y. H.","year":"2013","unstructured":"Ko Y. H.; Compositions and methods for the treatment of cancer. US20130157925A1 2013","journal-title":"US20130157925A1"},{"key":"ref=163","author":"Ko Y. H.","year":"2015","unstructured":"Ko Y. H.; Compositions and methods for the treatment of cancer. US9149449B2 2015","journal-title":"US9149449B2"},{"key":"ref=164","author":"Ko Y. H.","year":"2017","unstructured":"Ko Y. H.; Compositions and methods for the treatment of cancer. US9849103B2 2017","journal-title":"US9849103B2"},{"key":"ref=165","author":"Ko Y. H.","year":"2003","unstructured":"Ko Y. H.; Geschwind J.-F.; Pedersen P.; Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production. US20030087961A1 2003","journal-title":"US20030087961A1"},{"key":"ref=166","author":"Ko Y. H.","year":"2009","unstructured":"Ko Y. H.; Geschwind J.-F. H.; Pedersen P. L.; Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production US20090326068A1 2009","journal-title":"US20090326068A1"},{"key":"ref=167","author":"Geschwind J.-F.","year":"2010","unstructured":"Geschwind J.-F.; Vali M.; Therapeutics for cancer using 3- bromopyruvate and other selective inhibitors of ATP production. US20100203110A1 2010","journal-title":"US20100203110A1"},{"key":"ref=168","author":"Geschwind J.-F.","year":"2013","unstructured":"Geschwind J.-F.; Vali M.; Methods of treatment using 3- bromopyruvate and other selective inhibitors of ATP production. US20130046019A1 2013","journal-title":"US20130046019A1"},{"key":"ref=169","author":"Tidmarsh G.","year":"2004","unstructured":"Tidmarsh G.; Treatment of cancer with 2-Deoxyglucose. WO2004062604A2 2004","journal-title":"WO2004062604A2"},{"key":"ref=170","author":"Lampidis T. J.","year":"2003","unstructured":"Lampidis T. J.; Priebe W.; Cancer chemotherapy with 2- Deoxy-D-Glucose. US6670330B1 2003","journal-title":"US6670330B1"},{"key":"ref=171","author":"Yao J.","year":"2012","unstructured":"Yao J.; Brinton R. D.; Cancer chemotherapy with 2-Deoxy- D-Glucose. US6670330B1 2012","journal-title":"US6670330B1"},{"key":"ref=172","author":"Tidmarsh G.","year":"2007","unstructured":"Tidmarsh G.; Ammons S.; Treating metabolic syndrome with 2-Deoxy-D-Glucose. WO2007044679A2 2007","journal-title":"WO2007044679A2"},{"key":"ref=173","author":"Priebe W.","year":"2016","unstructured":"Priebe W.; Cybulski M.; Fokt I.; Skora S.; Conrad C.; Madden T.; Esters of 2-Deoxy-Monosacharides with antiproliferative activity. US20160184336A1 2016","journal-title":"US20160184336A1"},{"key":"ref=174","author":"Lampidis T. J.","year":"2016","unstructured":"Lampidis T. J.; Kurtoglu M.; Liu H.; Combination therapy with fenofibrate and 2-deoxyglucose or 2-deoxymannose. WO201665353A1 2016","journal-title":"WO201665353A1"},{"key":"ref=175","author":"Laudau B. R.","year":"2007","unstructured":"Laudau B. R.; Treatment of cancer with 2-Deoxygalactose. CA2655614 2007","journal-title":"CA2655614"},{"key":"ref=176","first-page":"267","volume":"24","author":"Laszlo J.","year":"1960","unstructured":"Laszlo J.; Humphreys S.R.; Goldin A.; Effects of glucose analogues (2-deoxy-D-glucose, 2-deoxy-D-galactose) on experimental tumors. J Natl Cancer Inst 1960,24(2),267-281","journal-title":"J Natl Cancer Inst"},{"key":"ref=177","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/S0021-9258(18)64100-6","volume":"236","author":"Barban S.","year":"1961","unstructured":"Barban S.; Schulze H.O.; The effects of 2-deoxyglucose on the growth and metabolism of cultured human cells. J Biol Chem 1961,236(7),1887-1890","journal-title":"J Biol Chem"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.rvsc.2017.07.035","volume":"114","author":"Arbe M.F.","year":"2017","unstructured":"Arbe M.F.; Fondello C.; Agnetti L.; \u00c1lvarez G.M.; Tellado M.N.; Glikin G.C.; Finocchiaro L.M.E.; Villaverde M.S.; Inhibition of bioenergetic metabolism by the combination of metformin and 2-deoxyglucose highly decreases viability of feline mammary carcinoma cells. Res Vet Sci 2017,114,461-468","journal-title":"Res Vet Sci"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1089\/ars.2007.1714","volume":"9","author":"Kurtoglu M.","year":"2007","unstructured":"Kurtoglu M.; Maher J.C.; Lampidis T.J.; Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells. Antioxid Redox Signal 2007,9(9),1383-1390","journal-title":"Antioxid Redox Signal"},{"key":"ref=180","author":"Tidmarsh G.","year":"2005","unstructured":"Tidmarsh G.; Treatment of Cancer with 2-Deoxyglucose. US6979675B2 2005","journal-title":"US6979675B2"},{"key":"ref=181","first-page":"391","volume":"23","author":"Baron J.C.","year":"1982","unstructured":"Baron J.C.; Lebrun-Grandie P.; Collard P.; Crouzel C.; Mestelan G.; Bousser M.G.; Noninvasive measurement of blood flow, oxygen consumption, and glucose utilization in the same brain regions in man by positron emission tomography: concise communication. J Nucl Med 1982,23(5),391-399","journal-title":"J Nucl Med"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/0003-9861(89)90135-5","volume":"269","author":"Wilson J.E.","year":"1989","unstructured":"Wilson J.E.; Chung V.; Rat brain hexokinase: further studies on the specificity of the hexose and hexose 6-phosphate binding sites. Arch Biochem Biophys 1989,269(2),517-525","journal-title":"Arch Biochem Biophys"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1432-1033.1990.tb15539.x","volume":"190","author":"Gr\u00fcn B.R.","year":"1990","unstructured":"Gr\u00fcn B.R.; Berger U.; Oberdorfer F.; Hull W.E.; Ostertag H.; Friedrich E.; Lehmann J.; Keppler D.; Metabolism and actions of 2-deoxy-2-fluoro-D-galactose in vivo. Eur J Biochem 1990,190(1),11-19","journal-title":"Eur J Biochem"},{"key":"ref=184","first-page":"359","volume":"7","author":"Courtois P.","year":"2001","unstructured":"Courtois P.; Sener A.; Malaisse W.J.; D-mannoheptulose phosphorylation by hexokinase isoenzymes. Int J Mol Med 2001,7(4),359-363","journal-title":"Int J Mol Med"},{"key":"ref=185","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1042\/bj0910056","volume":"91","author":"Coore H.G.","year":"1964","unstructured":"Coore H.G.; Randle P.J.; Inhibition of glucose phosphorylation by mannoheptulose. Biochem J 1964,91(1),56-59","journal-title":"Biochem J"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1023\/A:1006812300200","volume":"187","author":"Scruel O.","year":"1998","unstructured":"Scruel O.; Vanhoutte C.; Sener A.; Malaisse W.J.; Interference of D-mannoheptulose with D-glucose phosphorylation, metabolism and functional effects: comparison between liver, parotid cells and pancreatic islets. Mol Cell Biochem 1998,187(1-2),113-120","journal-title":"Mol Cell Biochem"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/(SICI)1099-0844(199903)17:1<65:AID-CBF812>3.0.CO;2-T","volume":"17","author":"Picton S.","year":"1999","unstructured":"Picton S.; Malaisse W.J.; Environmental modulation of the inhibitory action of D-mannoheptulose upon D-glucose metabolism in isolated rat pancreatic islets. Cell Biochem Funct 1999,17(1),65-71","journal-title":"Cell Biochem Funct"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/15216549800201662","volume":"44","author":"Malaisse W.J.","year":"1998","unstructured":"Malaisse W.J.; Kadiata M.M.; Scruel O.; Sener A.; Esterification of D-mannoheptulose confers to the heptose inhibitory action on D-glucose metabolism in parotid cells. Biochem Mol Biol Int 1998,44(3),625-633","journal-title":"Biochem Mol Biol Int"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1200\/JCO.2003.03.034","volume":"21","author":"Papaldo P.","year":"2003","unstructured":"Papaldo P.; Lopez M.; Cortesi E.; Cammilluzzi E.; Antimi M.; Terzoli E.; Lepidini G.; Vici P.; Barone C.; Ferretti G.; Di Cosimo S.; Nistic\u00f2 C.; Carlini P.; Conti F.; Di Lauro L.; Botti C.; Vitucci C.; Fabi A.; Giannarelli D.; Marolla P.; Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. J Clin Oncol 2003,21(18),3462-3468","journal-title":"J Clin Oncol"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1074\/jbc.M115.697516","volume":"291","author":"Guo L.","year":"2016","unstructured":"Guo L.; Shestov A.A.; Worth A.J.; Nath K.; Nelson D.S.; Leeper D.B.; Glickson J.D.; Blair I.A.; Inhibition of mitochondrial complex II by the anticancer agent lonidamine. J Biol Chem 2016,291(1),42-57","journal-title":"J Biol Chem"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.21873\/anticanres.11708","volume":"37","author":"Nath K.","year":"2017","unstructured":"Nath K.; Nelson D.S.; Roman J.; Putt M.E.; Lee S.C.; Leeper D.B.; Glickson J.D.; Effect of lonidamine on systemic therapy of DB-1 human melanoma xenografts with Temozolomide. Anticancer Res 2017,37(7),3413-3421","journal-title":"Anticancer Res"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0304-3835(01)00667-X","volume":"173","author":"Ko Y.H.","year":"2001","unstructured":"Ko Y.H.; Pedersen P.L.; Geschwind J.F.; Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 2001,173(1),83-91","journal-title":"Cancer Lett"},{"key":"ref=193","author":"Huang P.","year":"2006","unstructured":"Huang P.; Keating M. J.; Xu R.; Propyl 3-bromo-2-oxopropionate and derivatives as novel anticancer agents. US20060058383A1 2006","journal-title":"US20060058383A1"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.molonc.2008.01.003","volume":"2","author":"Ihrlund L.S.","year":"2008","unstructured":"Ihrlund L.S.; Hernlund E.; Khan O.; Shoshan M.C.; 3-Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs. Mol Oncol 2008,2(1),94-101","journal-title":"Mol Oncol"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.bbrc.2004.09.047","volume":"324","author":"Ko Y.H.","year":"2004","unstructured":"Ko Y.H.; Smith B.L.; Wang Y.; Pomper M.G.; Rini D.A.; Torbenson M.S.; Hullihen J.; Pedersen P.L.; Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 2004,324(1),269-275","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1124\/jpet.113.206714","volume":"348","author":"Calvi\u00f1o E.","year":"2014","unstructured":"Calvi\u00f1o E.; Esta\u00f1 M.C.; S\u00e1nchez-Mart\u00edn C.; Brea R.; de Blas E.; Boyano-Ad\u00e1nez, Mdel.C.; Rial, E.; Aller, P. Regulation of death induction and chemosensitizing action of 3-bromopyruvate in myeloid leukemia cells: energy depletion, oxidative stress, and protein kinase activity modulation. J Pharmacol Exp Ther 2014,348(2),324-335","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1093\/neuonc\/nou143","volume":"17","author":"Wicks R.T.","year":"2015","unstructured":"Wicks R.T.; Azadi J.; Mangraviti A.; Zhang I.; Hwang L.; Joshi A.; Bow H.; Hutt-Cabezas M.; Martin K.L.; Rudek M.A.; Zhao M.; Brem H.; Tyler B.M.; Local delivery of cancer-cell glycolytic inhibitors in high-grade glioma. Neuro-oncol 2015,17(1),70-80","journal-title":"Neuro-oncol"},{"key":"ref=198","doi-asserted-by":"publisher","DOI":"10.3390\/nano8010034","volume":"8","author":"Hanafy N.A.","year":"2018","unstructured":"Hanafy N.A.; Dini L.; Citti C.; Cannazza G.; Leporatti S.; Inihibition of glycolysis by using a micro\/nano-lipid bromopyruvic chitosan carrier as a promising tool to improve treatment of hepatocellular carcinoma. Nanomaterials (Basel) 2018,8(1)","journal-title":"Nanomaterials (Basel)"},{"key":"ref=199","first-page":"4405","volume":"10","author":"Gandham S.K.","year":"2015","unstructured":"Gandham S.K.; Talekar M.; Singh A.; Amiji M.M.; Inhibition of hexokinase-2 with targeted liposomal 3-bromopyruvate in an ovarian tumor spheroid model of aerobic glycolysis. Int J Nanomedicine 2015,10,4405-4423","journal-title":"Int J Nanomedicine"},{"key":"ref=200","doi-asserted-by":"publisher","DOI":"10.1126\/science.aah7192","author":"Feldwisch-Drentrup H.","year":"2016","unstructured":"Feldwisch-Drentrup H.; Candidate cancer drug suspected after death of three patients at an alternative medicine clinic. Science 2016","journal-title":"Science"},{"key":"ref=201","year":"2013","unstructured":"PreScience Labs Announced that the FDA Accepts IND Application for Novel Oncology Drug Business WireAvailable at: https:\/\/www.businesswire.com\/news\/home\/20130724006023\/en\/PreScience-Labs-Announced-FDA-Accepts-IND-Application2013","journal-title":"PreScience Labs Announced that the FDA Accepts IND Application for Novel Oncology Drug"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1038\/srep02070","volume":"3","author":"Salani B.","year":"2013","unstructured":"Salani B.; Marini C.; Rio A.D.; Ravera S.; Massollo M.; Orengo A.M.; Amaro A.; Passalacqua M.; Maffioli S.; Pfeffer U.; Cordera R.; Maggi D.; Sambuceti G.; Metformin impairs glucose consumption and survival in Calu-1 cells by direct inhibition of hexokinase-II. Sci Rep 2013,3,2070","journal-title":"Sci Rep"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.4161\/cc.26461","volume":"12","author":"Marini C.","year":"2013","unstructured":"Marini C.; Salani B.; Massollo M.; Amaro A.; Esposito A.I.; Orengo A.M.; Capitanio S.; Emionite L.; Riondato M.; Bottoni G.; Massara C.; Boccardo S.; Fabbi M.; Campi C.; Ravera S.; Angelini G.; Morbelli S.; Cilli M.; Cordera R.; Truini M.; Maggi D.; Pfeffer U.; Sambuceti G.; Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer. Cell Cycle 2013,12(22),3490-3499","journal-title":"Cell Cycle"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"105536","DOI":"10.18632\/oncotarget.22317","volume":"8","author":"Kang Y.T.","year":"2017","unstructured":"Kang Y.T.; Hsu W.C.; Wu C.H.; Hsin I.L.; Wu P.R.; Yeh K.T.; Ko J.L.; Metformin alleviates nickel-induced autophagy and apoptosis via inhibition of hexokinase-2, activating lipocalin-2, in human bronchial epithelial cells. Oncotarget 2017,8(62),105536-105552","journal-title":"Oncotarget"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrendo.2013.256","volume":"10","author":"Pernicova I.","year":"2014","unstructured":"Pernicova I.; Korbonits M.; Metformin--mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 2014,10(3),143-156","journal-title":"Nat Rev Endocrinol"},{"key":"ref=206","unstructured":"US National Library of Medicine- clinicaltrials.gov Available at: ClinicalTrials.gov (Accessed Date: 28 Feb, 2018)"},{"key":"ref=207","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0021-9258(18)70925-3","volume":"214","author":"Maley F.","year":"1955","unstructured":"Maley F.; Lardy H.A.; Synthesis of N-substituted glucosamines and their effect on hexokinase. J Biol Chem 1955,214(2),765-773","journal-title":"J Biol Chem"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3109\/14756369309020177","volume":"6","author":"Coats E.A.","year":"1992","unstructured":"Coats E.A.; Skau K.A.; Caperelli C.A.; Solomacha D.; Exploring the hexokinase glucose binding site through correlation analysis and molecular modeling of glucosamine inhibitors. J Enzyme Inhib 1992,6(4),271-282","journal-title":"J Enzyme Inhib"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13046-017-0530-4","volume":"36","author":"Li W.","year":"2017","unstructured":"Li W.; Zheng M.; Wu S.; Gao S.; Yang M.; Li Z.; Min Q.; Sun W.; Chen L.; Xiang G.; Li H.; Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2. J Exp Clin Cancer Res 2017,36(1),58","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.fitote.2018.01.001","volume":"125","author":"Bao F.","year":"2018","unstructured":"Bao F.; Yang K.; Wu C.; Gao S.; Wang P.; Chen L.; Li H.; New natural inhibitors of hexokinase 2 (HK2): Steroids from Ganoderma sinense. Fitoterapia 2018,125,123-129","journal-title":"Fitoterapia"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1002\/cmdc.201700592","volume":"12","author":"Flaherty D.P.","year":"2017","unstructured":"Flaherty D.P.; Harris M.T.; Schroeder C.E.; Khan H.; Kahney E.W.; Hackler A.L.; Patrick S.L.; Weiner W.S.; Aub\u00e9 J.; Sharlow E.R.; Morris J.C.; Golden J.E.; Optimization and evaluation of antiparasitic benzamidobenzoic acids as inhibitors of kinetoplastid hexokinase\u20051. ChemMedChem 2017,12(23),1994-2005","journal-title":"ChemMedChem"},{"key":"ref=212","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000659","volume":"4","author":"Sharlow E.R.","year":"2010","unstructured":"Sharlow E.R.; Lyda T.A.; Dodson H.C.; Mustata G.; Morris M.T.; Leimgruber S.S.; Lee K.H.; Kashiwada Y.; Close D.; Lazo J.S.; Morris J.C.; A target-based high throughput screen yields Trypanosoma brucei hexokinase small molecule inhibitors with antiparasitic activity. PLoS Negl Trop Dis 2010,4(4)","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.bmcl.2016.12.021","volume":"27","author":"Gordhan H.M.","year":"2017","unstructured":"Gordhan H.M.; Patrick S.L.; Swasy M.I.; Hackler A.L.; Anayee M.; Golden J.E.; Morris J.C.; Whitehead D.C.; Evaluation of substituted ebselen derivatives as potential trypanocidal agents. Bioorg Med Chem Lett 2017,27(3),537-541","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=214","author":"Sharlow E.","unstructured":"Sharlow E.; Golden J.E.; Dodson H.; Morris M.; Hesser M.; Lyda T.; Leimgruber S.; Shroeder C.E.; Flaherty D.P.; Weiner W.S.; Simpson D.; Lazo J.S.; Aub\u00e9 J.; al Morris J.C.; Identification of inhibitors of Trypanosoma brucei hexokinases. Probe Reports from the NIH Molecular Libraries Program [Internet], 2011. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK63599\/ (Accessed Date: 28 Feb, 2018)","journal-title":"Probe Reports from the NIH Molecular Libraries Program [Internet],"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"8735","DOI":"10.1039\/C7CC03378H","volume":"53","author":"Gordhan H.M.","year":"2017","unstructured":"Gordhan H.M.; Milanes J.E.; Qiu Y.; Golden J.E.; Christensen K.A.; Morris J.C.; Whitehead D.C.; A targeted delivery strategy for the development of potent trypanocides. Chem Commun (Camb) 2017,53(62),8735-8738","journal-title":"Chem Commun (Camb)"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3109\/14756366.2013.779265","volume":"29","author":"Saucedo-Mendiola M.L.","year":"2014","unstructured":"Saucedo-Mendiola M.L.; Salas-Pacheco J.M.; N\u00e1jera H.; Rojo-Dom\u00ednguez A.; Y\u00e9pez-Mulia L.; Avitia-Dom\u00ednguez C.; T\u00e9llez-Valencia A.; Discovery of Entamoeba histolytica hexokinase 1 inhibitors through homology modeling and virtual screening. J Enzyme Inhib Med Chem 2014,29(3),325-332","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1016\/0006-2952(85)90359-4","volume":"34","author":"Tielens A.G.M.","year":"1985","unstructured":"Tielens A.G.M.; Houweling M.; Van den Bergh S.G.; The effect of 5-thioglucose on the energy metabolism of Schistosoma mansoni in vitro. Biochem Pharmacol 1985,34(18),3369-3373","journal-title":"Biochem Pharmacol"},{"key":"ref=218","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3109\/14756369709035812","volume":"12","author":"Willson M.","year":"1997","unstructured":"Willson M.; Alric I.; Perie J.; Sanejouand Y.H.; Yeast hexokinase inhibitors designed from the 3-D enzyme structure rebuilding. J Enzyme Inhib 1997,12(2),101-121","journal-title":"J Enzyme Inhib"},{"key":"ref=219","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.molbiopara.2007.12.013","volume":"158","author":"Chambers J.W.","year":"2008","unstructured":"Chambers J.W.; Fowler M.L.; Morris M.T.; Morris J.C.; The anti-trypanosomal agent lonidamine inhibits Trypanosoma brucei hexokinase 1. Mol Biochem Parasitol 2008,158(2),202-207","journal-title":"Mol Biochem Parasitol"},{"key":"ref=220","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1038\/onc.2008.108","volume":"27","author":"Goldin N.","year":"2008","unstructured":"Goldin N.; Arzoine L.; Heyfets A.; Israelson A.; Zaslavsky Z.; Bravman T.; Bronner V.; Notcovich A.; Shoshan-Barmatz V.; Flescher E.; Methyl jasmonate binds to and detaches mitochondria-bound hexokinase. Oncogene 2008,27(34),4636-4643","journal-title":"Oncogene"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00280-012-2039-z","volume":"71","author":"Raviv Z.","year":"2013","unstructured":"Raviv Z.; Cohen S.; Reischer-Pelech D.; The anti-cancer activities of jasmonates. Cancer Chemother Pharmacol 2013,71(2),275-285","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1074\/jbc.M803614200","volume":"284","author":"Arzoine L.","year":"2009","unstructured":"Arzoine L.; Zilberberg N.; Ben-Romano R.; Shoshan-Barmatz V.; Voltage-dependent anion channel 1-based peptides interact with hexokinase to prevent its anti-apoptotic activity. J Biol Chem 2009,284(6),3946-3955","journal-title":"J Biol Chem"},{"key":"ref=223","volume":"4e809","author":"Prezma T.","year":"2013","unstructured":"Prezma T.; Shteinfer A.; Admoni L.; Raviv Z.; Sela I.; Levi I.; Shoshan-Barmatz V.; VDAC1-based peptides: novel pro-apoptotic agents and potential therapeutics for Bcell chronic lymphocytic leukemia. Cell Death Dis 2013,4e809","journal-title":"Cell Death Dis"},{"key":"ref=224","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1096\/fj.201601173R","volume":"31","author":"Woldetsadik A.D.","year":"2017","unstructured":"Woldetsadik A.D.; Vogel M.C.; Rabeh W.M.; Magzoub M.; Hexokinase II-derived cell-penetrating peptide targets mitochondria and triggers apoptosis in cancer cells. FASEB J 2017,31(5),2168-2184","journal-title":"FASEB J"},{"key":"ref=225","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13024-017-0212-x","volume":"12","author":"Hauser D.N.","year":"2017","unstructured":"Hauser D.N.; Mamais A.; Conti M.M.; Primiani C.T.; Kumaran R.; Dillman A.A.; Langston R.G.; Beilina A.; Garcia J.H.; Diaz-Ruiz A.; Bernier M.; Fiesel F.C.; Hou X.; Springer W.; Li Y.; de Cabo R.; Cookson M.R.; Hexokinases link DJ-1 to the PINK1\/parkin pathway. Mol Neurodegener 2017,12(1),70","journal-title":"Mol Neurodegener"},{"key":"ref=226","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191533","volume":"13","author":"Varanasi S.K.","year":"2018","unstructured":"Varanasi S.K.; Jaggi U.; Hay N.; Rouse B.T.; Hexokinase II may be dispensable for CD4 T cell responses against a virus infection. PLoS One 2018,13(1)","journal-title":"PLoS One"},{"key":"ref=227","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jot.2017.12.004","volume":"12","author":"Wang C.","year":"2018","unstructured":"Wang C.; Silverman R.M.; Shen J.; O\u2019Keefe R.J.; Distinct metabolic programs induced by TGF-\u03b21 and BMP2 in human articular chondrocytes with osteoarthritis. J Orthop Translat 2018,12,66-73","journal-title":"J Orthop Translat"},{"key":"ref=228","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/jnc.14267","volume":"144","author":"Li Y.","year":"2018","unstructured":"Li Y.; Lu B.; Sheng L.; Zhu Z.; Sun H.; Zhou Y.; Yang Y.; Xue D.; Chen W.; Tian X.; Du Y.; Yan M.; Zhu W.; Xing F.; Li K.; Lin S.; Qiu P.; Su X.; Huang Y.; Yan G.; Yin W.; Hexokinase 2-dependent hyperglycolysis driving microglial activation contributes to ischemic brain injury. J Neurochem 2018,144(2),186-200","journal-title":"J Neurochem"},{"key":"ref=229","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.cell.2006.05.036","volume":"126","author":"Bensaad K.","year":"2006","unstructured":"Bensaad K.; Tsuruta A.; Selak M.A.; Vidal M.N.C.; Nakano K.; Bartrons R.; Gottlieb E.; Vousden K.H.; TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006,126(1),107-120","journal-title":"Cell"},{"key":"ref=230","doi-asserted-by":"publisher","first-page":"20491","DOI":"10.1073\/pnas.1206530109","volume":"109","author":"Cheung E.C.","year":"2012","unstructured":"Cheung E.C.; Ludwig R.L.; Vousden K.H.; Mitochondrial localization of TIGAR under hypoxia stimulates HK2 and lowers ROS and cell death. Proc Natl Acad Sci USA 2012,109(50),20491-20496","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=231","author":"Robles L\u00f3pez K.L.","unstructured":"Robles L\u00f3pez K.L.; The role of TIGAR in Parkinson\u2019s disease, 2017. Available at: ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/etheses.whiterose.ac.uk\/id\/eprint\/18939\">http:\/\/etheses.whiterose.ac.uk\/id\/eprint\/18939(Accessed Date: 13 March,2018)"},{"key":"ref=232","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.bbrc.2012.10.041","volume":"428","author":"Okatsu K.","year":"2012","unstructured":"Okatsu K.; Iemura S.; Koyano F.; Go E.; Kimura M.; Natsume T.; Tanaka K.; Matsuda N.; Mitochondrial hexokinase HKI is a novel substrate of the Parkin ubiquitin ligase. Biochem Biophys Res Commun 2012,428(1),197-202","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=233","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/hmg\/ddt407","volume":"23","author":"McCoy M.K.","year":"2014","unstructured":"McCoy M.K.; Kaganovich A.; Rudenko I.N.; Ding J.; Cookson M.R.; Hexokinase activity is required for recruitment of parkin to depolarized mitochondria. Hum Mol Genet 2014,23(1),145-156","journal-title":"Hum Mol Genet"},{"key":"ref=234","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.yexcr.2015.11.016","volume":"340","author":"Ghosh S.","year":"2016","unstructured":"Ghosh S.; Gupta P.; Sen E.; TNF\u03b1 driven HIF-1\u03b1-hexokinase II axis regulates MHC-I cluster stability through actin cytoskeleton. Exp Cell Res 2016,340(1),116-124","journal-title":"Exp Cell Res"},{"key":"ref=235","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.cell.2016.05.076","volume":"166","author":"Wolf A.J.","year":"2016","unstructured":"Wolf A.J.; Reyes C.N.; Liang W.; Becker C.; Shimada K.; Wheeler M.L.; Cho H.C.; Popescu N.I.; Coggeshall K.M.; Arditi M.; Underhill D.M.; Hexokinase is an innate immune receptor for the detection of bacterial peptidoglycan. Cell 2016,166(3),624-636","journal-title":"Cell"},{"key":"ref=236","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1253\/circj.CJ-15-0394","volume":"79","author":"Okuyama N.","year":"2015","unstructured":"Okuyama N.; Matsuda S.; Yamashita A.; Moriguchi-Goto S.; Sameshima N.; Iwakiri T.; Matsuura Y.; Sato Y.; Asada Y.; Human coronary thrombus formation is associated with degree of plaque disruption and expression of tissue factor and hexokinase II. Circ J 2015,79(11),2430-2438","journal-title":"Circ J"},{"key":"ref=237","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068376","volume":"8","author":"Barrero C.A.","year":"2013","unstructured":"Barrero C.A.; Datta P.K.; Sen S.; Deshmane S.; Amini S.; Khalili K.; Merali S.; HIV-1 Vpr modulates macrophage metabolic pathways: a SILAC-based quantitative analysis. PLoS One 2013,8(7)","journal-title":"PLoS One"},{"key":"ref=238","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1016\/j.bmcl.2016.10.085","volume":"27","author":"Xu J.","year":"2017","unstructured":"Xu J.; Lin S.; Myers R.W.; Addona G.; Berger J.P.; Campbell B.; Chen H.S.; Chen Z.; Eiermann G.J.; Elowe N.H.; Farrer B.T.; Feng W.; Fu Q.; Kats-Kagan R.; Kavana M.; Malkani S.; McMasters D.R.; Mitra K.; Pachanski M.J.; Tong X.; Trujillo M.E.; Xu L.; Zhang B.; Zhang F.; Zhang R.; Parmee E.R.; Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus. Bioorg Med Chem Lett 2017,27(9),2069-2073","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=239","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s001250050850","volume":"40","author":"Malkki M.","year":"1997","unstructured":"Malkki M.; Laakso M.; Deeb S.S.; The human hexokinase II gene promoter: functional characterization and detection of variants among patients with NIDDM. Diabetologia 1997,40(12),1461-1469","journal-title":"Diabetologia"},{"key":"ref=240","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.209","volume":"6","author":"Courteau L.","year":"2015","unstructured":"Courteau L.; Crasto J.; Hassanzadeh G.; Baird S.D.; Hodgins J.; Liwak-Muir U.; Fung G.; Luo H.; Stojdl D.F.; Screaton R.A.; Holcik M.; Hexokinase 2 controls cellular stress response through localization of an RNA-binding protein. Cell Death Dis 2015,6","journal-title":"Cell Death Dis"},{"key":"ref=241","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1074\/jbc.M117.816785","volume":"293","author":"Sheikh T.","year":"2018","unstructured":"Sheikh T.; Gupta P.; Gowda P.; Patrick S.; Sen E.; Hexokinase 2 and nuclear factor erythroid 2-related factor 2 transcriptionally coactivate xanthine oxidoreductase expression in stressed glioma cells. J Biol Chem 2018,293(13),4767-4777","journal-title":"J Biol Chem"},{"key":"ref=242","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1042\/EBC20170052","volume":"61","author":"van Montfort R.L.M.","year":"2017","unstructured":"van Montfort R.L.M.; Workman P.; Structure-based drug design: aiming for a perfect fit. Essays Biochem 2017,61(5),431-437","journal-title":"Essays Biochem"},{"key":"ref=243","author":"Stewart B.W.","year":"2014","unstructured":"Stewart B.W.; Wild C.P.; World Cancer Report 2014","journal-title":"World Cancer Report"},{"key":"ref=244","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/13696998.2017.1282865","volume":"20","author":"Mendoza R.L.","year":"2017","unstructured":"Mendoza R.L.; The 21st Century Cures Act: pharmacoeconomic boon or bane? J Med Econ 2017,20(4),315-317","journal-title":"J Med Econ"},{"key":"ref=245","doi-asserted-by":"publisher","first-page":"875","DOI":"10.2174\/1568026616666160818152257","volume":"17","author":"Kleczkowska P.","year":"2017","unstructured":"Kleczkowska P.; Kowalczyk A.; Lesniak A.; Bujalska-Zadrozny M.; The discovery and development of drug combinations for the treatment of various diseases from patent literature (1980-Present). Curr Top Med Chem 2017,17(8),875-894","journal-title":"Curr Top Med Chem"},{"key":"ref=246","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMsb1607705","volume":"375","author":"Tannock I.F.","year":"2016","unstructured":"Tannock I.F.; Hickman J.A.; Limits to personalized cancer medicine. N Engl J Med 2016,375(13),1289-1294","journal-title":"N Engl J Med"},{"key":"ref=247","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"Holohan C.","year":"2013","unstructured":"Holohan C.; Van Schaeybroeck S.; Longley D.B.; Johnston P.G.; Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013,13(10),714-726","journal-title":"Nat Rev Cancer"},{"key":"ref=248","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nrc.2016.100","volume":"16","author":"Cairns R.A.","year":"2016","unstructured":"Cairns R.A.; Mak T.W.; The current state of cancer metabolism. Nat Rev Cancer 2016,16(10),613-614","journal-title":"Nat Rev Cancer"},{"key":"ref=249","doi-asserted-by":"publisher","first-page":"4777","DOI":"10.1038\/sj.onc.1209603","volume":"25","author":"Mathupala S.P.","year":"2006","unstructured":"Mathupala S.P.; Ko Y.H.; Pedersen P.L.; Hexokinase II: cancer\u2019s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 2006,25(34),4777-4786","journal-title":"Oncogene"},{"key":"ref=250","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nature15818","volume":"526","author":"Naldini L.","year":"2015","unstructured":"Naldini L.; Gene therapy returns to centre stage. Nature 2015,526(7573),351-360","journal-title":"Nature"},{"key":"ref=251","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nm.3793","volume":"21","author":"Cox D.B.T.","year":"2015","unstructured":"Cox D.B.T.; Platt R.J.; Zhang F.; Therapeutic genome editing: prospects and challenges. Nat Med 2015,21(2),121-131","journal-title":"Nat Med"},{"key":"ref=252","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ijpharm.2013.11.041","volume":"459","author":"Ibraheem D.","year":"2014","unstructured":"Ibraheem D.; Elaissari A.; Fessi H.; Gene therapy and DNA delivery systems. Int J Pharm 2014,459(1-2),70-83","journal-title":"Int J Pharm"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/168321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T04:32:41Z","timestamp":1662611561000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/168321\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,8]]},"references-count":252,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2020,1,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867326666181213092652","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-07-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}